MedTrace Logo

Study to Evaluate the Efficacy and Safety of DA-1241 in Subjects With Presumed NASH

NCT06054815 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 109

Last updated 2024-11-14

No results posted yet for this study

Summary

A multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 2a clinical trial to evaluate the efficacy and safety of DA 1241 in subjects with presumed non-alcoholic steatohepatitis (NASH).

Conditions

  • NON-ALCOHOLIC STEATOHEPATITIS

Interventions

DRUG

DA-1241

Route of Administration: Oral, with subjects in a fasting state

DRUG

Sitagliptin

Route of Administration: Oral, with subjects in a fasting state

DRUG

DA-1241 Placebo

Route of Administration: Oral, with subjects in a fasting state

DRUG

Sitagliptin Placebo

Route of Administration: Oral, with subjects in a fasting state

Sponsors & Collaborators

  • NeuroBo Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-14
Primary Completion
2024-10-24
Completion
2024-10-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06054815 on ClinicalTrials.gov